ecancer
ecancer is a UK charity which provides accessible, high-quality educational content, free to the global oncology community. Our mission is to raise the standards of care for cancer patients across the world through education.
GI Cancers
ecancer
ESMO GI 2024 Insights: Paclitaxel and Ramucirumab in HER2- Advanced GC/GEJC - Ph3 ARMANI Trial
FEATURING
Giovanni Randon
- 41 views
- July 29, 2024
- 1
ecancer
ESMO GI 2024 Insights: Impact of Systemic Chemotherapy on Survival in Patients With Resectable CRC Liver Metastases
FEATURING
Giacomo Bregni
- 81 views
- July 29, 2024
ecancer
Targeting BRAF V600E in mCRC: Where Are We Today?
FEATURING
Rodrigo Motta Guerrero
- 84 views
- September 1, 2023
ecancer
Effectiveness and Tolerability of Cetuximab With XELOX or XELIRI in RAS Wild-Type mCRC
FEATURING
Jamal Zekri
- 15 views
- June 26, 2023
ecancer
Durable Effect of Imatinib & Metronomic Chemo With Capecitabine in Pancreatic Carcinoma
FEATURING
Sana Al-Sukhun
- 13 views
- June 26, 2023
ecancer
CheckMate 649 Trial Biomarker Analyses of Nivo + Ipi vs. Chemo for Patients With GC/GEJC/EAC
FEATURING
Yelena Y. Janjigian
- 231 views
- June 21, 2023
- 1
ecancer
Initial Results From a Phase 1 GLIMMER-01 Trial: Efficacy of Dose Escalation Study of E-602 in Solid Tumors
FEATURING
Jason Luke
- 75 views
- June 21, 2023
- 1
ecancer
CRYSTAL Trial: Left vs. Right Sided GI Tumor Response
FEATURING
Eric Van Cutsem
- 148 views
- October 31, 2022
ecancer
ESMO GI 2022 on CRC: Impact of BRAF-V600E Mutation on Tumor Microenvironment and Associated Genomic Alterations
FEATURING
Mohamed Salem
- 159 views
- September 7, 2022
- 1
ecancer
ESMO GI 2022 Update on MOUNTAINEER Trial: Tucatinib in Combination With Trastuzumab for HER2+ mCRC
FEATURING
Jonathan Strickler
- 65 views
- September 7, 2022
ecancer
Optimum Treatment Strategy Algorithm for mCRC
FEATURING
Heinz-Josef Lenz
- 410 views
- September 7, 2022
- 1
ecancer
An Overview of Treatment Advances in Gastric Cancer
FEATURING
David Ilson
- 327 views
- September 7, 2022
- 1
ecancer
Tumor Agnostic Treatments in GI Cancers: Liquid Bipsy, Biomarkers
FEATURING
Nicola Normanno,
Katja Schmitz
- 10 views
- April 13, 2022
ecancer
Tremelimumab and Durvalumab as 1L in Unresectable HCC: Phase 3 HIMALAYA Trial
FEATURING
Ghassan Abou-Alfa
- 257 views
- April 13, 2022
- 1
ecancer
Early Treatment Discontinuation and Early Oxaliplatin Discontinuation for Stage III CRC: ACCENT/IDEA Pooled Analysis
FEATURING
Claire Gallois
- 79 views
- April 13, 2022
ecancer
ASCO GI 2022: OS With Durvalumab + Chemo in Advanced Biliary Tract Cancer - TOPAZ-1 Phase III Trial
FEATURING
Do-Youn Oh
- 135 views
- April 13, 2022
ecancer
ESMO 2021 Updates on Adagrasib +/- Cetuximab for CRC Patients Harboring a KRASG12C Mutation
FEATURING
Jared Weiss
- 65 views
- October 22, 2021
ecancer
2L Yttrium-90 Radioembolization With Chemo for CRC Liver Metastases
FEATURING
Mary Mulcahy
- 31 views
- October 20, 2021
ecancer
ESMO 2021 Data on Anti-TIGIT Antibody Tiragolumab + Atezolizumab in Metastatic Esophageal Cancer
FEATURING
Zev A. Wainberg
- 388 views
- September 2, 2021
- 2
ecancer
ESMO 2021 Update on BRAFV600E mCRC: cfDNA BRAF Mutant Allele Fraction & Whole Exome Sequencing
FEATURING
Elena Elez
- 34 views
- September 2, 2021
ecancer
ESMO 2021 Data on 1L Bevacizumab in CRC With BRAF Mutation: BEACON CRC Trial
FEATURING
Dan Aderka
- 62 views
- September 2, 2021
ecancer
2020 ESMO Update on CheckMate 577: Does Nivolumab Demonstrate DFS Improvement in EC/GEJC Following Neoadjuvant CRT?
FEATURING
Ronan Kelly
- 156 views
- December 29, 2020
- 1
ecancer
2020 ESMO Update on CheckMate 459: What Are the OS Outcomes With 1L Nivo vs. Sor in Advanced HCC?
FEATURING
Bruno Sangro
- 87 views
- December 28, 2020
ecancer
2020 ESMO Update on 1L Non-HER2+ Advanced GC/GEJ/EC: Will Nivolumab + Chemotherapy Become a New SoC?
FEATURING
Markus Moehler
- 119 views
- November 30, 2020